OR WAIT null SECS
Decision is anticipated to boost operational efficiencies for the CDMO.
KBI Biopharma, Inc., a contract development and manufacturing organization (CDMO),
and Selexis SA, a cell line development company, are consolidating as one organization under the KBI Biopharma name. The fusion is expected to enable integrated, solutions for customers, cell line development through process development, to clinical and commercial cGMP manufacturing services for mammalian programs.
According to the parties, the streamlined operational approach supports customers in both drug development and manufacturing, creating flexibility and efficiencies, and a simplified partner experience. By bringing together the capabilities and expertise of KBI Biopharma and Selexis, customers can reduce manufacturing risks and deliver essential medicines to patients at a faster rate.
“The operational consolidation of these two exceptional companies represents a major shift in how KBI Biopharma will operate moving forward,” says J.D. Mowery, CEO of KBI Biopharma. “By providing fully integrated solutions for our customers, we will be a stronger partner that can help them each reach their goals more efficiently.”